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Abstract  158 
 159 
Background: The multi-morbid burden and use of systemic immunosuppressants in people 160 
with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited.  161 
Objective: Characterize the course of COVID-19 in psoriasis and identify factors associated 162 
with hospitalization. 163 
Methods: Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an 164 
international registry, PsoProtect. Multiple logistic regression assessed the association 165 
between clinical/demographic characteristics and hospitalization. A separate patient-facing 166 
registry characterized risk-mitigating behaviours.  167 
Results: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 168 
18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered 169 
from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization 170 
risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 171 
1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24-172 
8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was 173 
more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% 174 
CI 1.31-6.18). No significant differences were found between biologic classes. Independent 175 
patient-reported data (n=1,626 across 48 countries) suggested lower levels of social 176 
isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 177 
0.68, 95% CI 0.50-0.94). 178 
Conclusion: In this international moderate-severe psoriasis case series, biologics use was 179 
associated with lower risk of COVID-19-related hospitalization than non-biologic systemic 180 
therapies, however further investigation is warranted due to potential selection bias and 181 
unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, 182 
comorbidities) were associated with higher hospitalization rates. 183 
 184 
 185 
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Clinical Implications.  187 
We identify risk factors for COVID-19-related hospitalization in psoriasis patients, including 188 
older age, male sex, non-white ethnicity and comorbidities. Use of biologics was associated 189 
with lower hospitalization risk than non-biologic systemic therapies. 190 
 191 
 192 
Capsule summary  193 
In this global registry-based study, risk factors for COVID-19-related hospitalization in 194 
psoriasis patients were older age, male sex, non-white ethnicity and comorbidities. Use of 195 
biologics was associated with lower hospitalization risk than non-biologic systemic 196 
treatment. 197 
 198 
 199 
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Abbreviations 204 
COVID-19 (Coronavirus disease 2019), SARS-CoV-2 (severe acute respiratory syndrome 205 
coronavirus 2), IMID (immune-mediated inflammatory disease), IFN (interferon), IL 206 
(interleukin), TNF (tumor necrosis factor), JAK (Janus kinase), OR (odds ratio), 95% CI (95% 207 
confidence interval), IQR (interquartile range), PsoProtect (Psoriasis Patient Registry for 208 
Outcomes, Therapy and Epidemiology of COVID-19 infecTion), ACEi (angiotensin-converting 209 
enzyme inhibitor), ARB (angiotensin II receptor blocker), NSAID (non-steroidal anti-210 
inflammatory drug), BMI (body mass index).  211 
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Introduction 217 
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-218 
CoV-2), has led to unprecedented challenges for the international clinical and scientific 219 
community (1). Although most patients with COVID-19 experience mild symptoms, an 220 
estimated 15% develop pneumonia and 5% progress to systemic hyperinflammation and 221 
acute respiratory distress syndrome requiring critical care management, with risk of septic 222 
shock, multi-organ failure and death (2). Reported mortality rates range from 2.3% to 7.2% 223 
(2,3). Increased age, male sex and non-white ethnicity have emerged as risk factors of poor 224 
COVID-19 outcome in the general population, in addition to comorbidities including 225 
cardiovascular disease, diabetes and obesity (4–6). Since multimorbidity is prevalent in 226 
psoriasis (7), there is an urgent need to understand the impact of COVID-19 in individuals 227 
with this common lifelong immune-mediated skin disease. Psoriasis affects more than 60 228 
million people worldwide (8) and pre-COVID-19 observational data suggest greater risk of 229 
respiratory infection-related hospitalization compared to the general population(9). 230 
Furthermore, there is uncertainty about whether additional serious infection risk is 231 
conferred by immunosuppressant drugs, which are the mainstay of treatment in moderate-232 
severe psoriasis (10,11).  233 
The immune pathways implicated in the pathogenesis of psoriasis, as well as the drugs used 234 
to treat it, may differentially influence the clinical course of COVID-19. Psoriasis is 235 
characterized by dysregulated innate and adaptive immune responses, with type I 236 
interferon (IFN)-secreting dendritic cells propagating pathogenic interleukin (IL)-23/T17 237 
circuits (12). In the initial phase of COVID-19, viral pathogenicity is dominant, and viral 238 
clearance by early host type I IFN-mediated responses prevents further viral replication, T 239 
cell exhaustion and hyperinflammation (13). A reduced or delayed type I IFN response has 240 
been associated with poor COVID-19 outcomes (14); thus it is possible that the immune 241 
dysregulation in psoriasis may be advantageous, whilst its therapeutic suppression may be 242 
detrimental. The second phase of COVID-19 comprises hyperinflammation and cytokine 243 
storm, with elevation of pro-inflammatory cytokines also implicated in psoriasis including 244 
tumor necrosis factor (TNF), IL-1β, IL-6, IL-8, IFNγ and IL-17. It is unclear whether individuals 245 
with psoriasis are at greater risk of progression to this phase and conversely, whether 246 
immunosuppressants are effective therapies for severe COVID-19. Treatments targeting the 247 
over-exuberant host immune response in COVID-19, including inhibitors of IL-1, IL-6, Janus 248 
kinase (JAK) and TNF, are currently undergoing clinical trial (15,16).  249 
Psoriasis, rheumatoid arthritis and systemic lupus erythematosus were collectively 250 
highlighted as potential risk factors for COVID-19-related death using primary care data 251 
linked to hospital records from 17 million adults in the UK (6). However, the risk attributed 252 
to psoriasis alone or its therapies remains uncertain. Preliminary reports in individuals with 253 
psoriasis have not demonstrated higher levels of COVID-19-related hospitalization among 254 
those receiving biologic therapies (17–20). However, these data have limited external 255 
validity since the case series were all from Northern Italy and included few patients with 256 
adverse outcomes. There is thus an urgent need to collate reports of COVID-19 in psoriasis 257 
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to understand the determinants of severe infection and help inform clinical decision-258 
making. Here, we describe the first international series of psoriasis patients with COVID-19 259 
and identify demographic and clinical factors associated with hospitalization. 260 
 261 
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Methods  263 
Study Design, Setting, Participants 264 
This registry-based study comprised two data sources. The primary data source was an 265 
online clinician-reported registry, Psoriasis Patient Registry for Outcomes, Therapy and 266 
Epidemiology of COVID-19 infecTion (PsoProtect), which launched globally on 27 March 267 
2020 (21). Data were collected and managed using REDCap electronic data capture tools 268 
licensed to King’s College London Division of Health and Social Care Research (22,23). 269 
REDCap is a secure, web-based software platform designed to support data capture.  270 
The eligibility criterion was any patient with psoriasis and confirmed/suspected COVID-19 271 
identified by their supervising clinician. Case submission was requested at least 14 days 272 
following symptom onset, and once sufficient time had passed to observe the outcome of 273 
infection. Clinicians were invited to participate via the communication channels of multiple 274 
international professional organizations (Table E1). We also invited case reports from two 275 
United States COVID-19 registries (SECURE-Psoriasis, AAD COVID-19) (24,25). Thirty-eight of 276 
the cases are published elsewhere (n=29 (17) and n=9 (18)).  277 
The second data source was a separate online self-report patient-facing registry, 278 
PsoProtectMe, which launched globally on 4 May 2020. The eligibility criterion was a 279 
clinician-confirmed diagnosis of psoriasis, irrespective of COVID-19 status. Participants were 280 
invited via the communication channels of multiple international psoriasis patient 281 
organizations (Table E1).  282 
 283 
Variables 284 
Minimum sufficient core sets of variables within the PsoProtect and PsoProtectMe case 285 
report forms (26,27) were defined by our study group of clinicians, epidemiologists, health 286 
data researchers and patient representatives, aligned with those of other immune-mediated 287 
inflammatory disease (IMID) COVID-19 registries (28,29). Key variables in both registries 288 
included demographics (age, sex, ethnicity, country), smoking status, comorbidities, details 289 
of psoriasis (phenotype, treatment) and COVID-19 (symptoms, treatment, outcome). 290 
Medication adherence and social isolation behaviour during the pandemic were collected in 291 
PsoProtectMe.  292 
 293 
Statistical methods 294 
PsoProtect and PsoProtectMe data were extracted on 1 and 3 July 2020, respectively. 295 
Incomplete, duplicate and erroneous entries were manually reviewed by the study team 296 
and removed. All analysis was performed using the R statistical programming language (30). 297 
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Demographic and clinical characteristics and COVID-19 outcomes of the study population 298 
were summarized using descriptive statistics. Continuous variables were reported using 299 
median and interquartile range (IQR), and categorical/dichotomous variables as number and 300 
percentage. 301 
We used clinician-reported registry data to investigate the demographic and disease-specific 302 
factors associated with the primary outcome of hospitalization for COVID-19. The key 303 
exposure measure was treatment type for psoriasis at or up to four weeks prior to COVID-19 304 
onset, comprising: biologics (TNF inhibitors: adalimumab, certolizumab pegol, etanercept, 305 
infliximab, golimumab; IL-17 inhibitors: brodalumab, ixekizumab, secukinumab; IL12/IL-306 
23p40 or IL-23p19 [collectively IL-23] inhibitors: guselkumab, risankizumab, tildrakizumab, 307 
ustekinumab), non-biologic systemic agents (acitretin, apremilast, ciclosporin, 308 
methotrexate, fumaric acid esters/dimethylfumarate, prednisolone), and no systemic 309 
treatment.  310 
The association between treatment type (biologic, non-biologic systemic or no systemic 311 
treatment) and hospitalization for COVID-19 was assessed using: (a) a minimally adjusted 312 
logistic regression model including age and sex covariates; and (b) a fully adjusted model 313 
including a consensus list of covariates selected a priori as potentially influential on adverse 314 
COVID-19 outcome on the basis of expert clinical opinion and existing evidence (2,3,6,31), 315 
namely, age, sex, ethnicity, country, smoking, BMI and comorbidities. Other relevant 316 
variables (use of angiotensin-converting enzyme inhibitor, use of angiotensin II receptor 317 
blocker, obesity comorbidity) that correlated (|r|>0.5) with included covariates were 318 
excluded. Levels of categorical variables exhibiting small counts (<10 observations of either 319 
outcome) were merged. Comorbid obesity was assumed where BMI>30, even where not 320 
directly reported. Selection bias in missing data was explored by comparing patients with 321 
missing data for variables included in the fully adjusted model (BMI, smoking, or BMI and 322 
smoking) to patients with complete data (Table E2). Small differences were observed in 323 
proportions of men, white ethnicity, confirmed COVID-19 diagnosis and hospitalization. 324 
Therefore, to maximise included data, the final regression models were based on 20 325 
multiply imputed datasets generated with the Multivariate Imputation by Chained 326 
Equations (MICE) R package (32).  327 
Quadratic terms for age and sex covariates were considered but rejected due to lack of 328 
improvement in model fit (likelihood ratio test). Minimally and fully adjusted odds ratios 329 
(OR) and 95% confidence intervals (CI) were reported for each variable. Sensitivity analyses 330 
were performed on the fully adjusted multivariable regression models. To assess the 331 
association between biologic class and the primary outcome, a fully adjusted model was 332 
fitted in which treatment type was further categorized by biologic class (TNF, IL-17 or IL-23 333 
inhibitor). Improvement in fit relative to the original treatment type model was assessed 334 
using a likelihood ratio test. The STROBE statement for cross-sectional studies was used as a 335 
basis for reporting (33).  336 
 337 
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Ethical approval 338 
Ethical approval was granted by the Leeds Research Ethics Committee (20/YH/0135) and the 339 
study was registered in the European Union electronic Register of Post-Authorisation 340 
Studies (34). Only de-identified data were collected, hence written informed patient consent 341 
was not required. Data collection, transfer and storage were compliant with statutory 342 
requirements, ICH Good Clinical Practice and EU General Data Protection Regulation.  343 
 344 
345 
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Results 346 
Demographic and clinical characteristics of a global series of individuals with COVID-19 347 
and psoriasis  348 
In total, 374 psoriasis patients with confirmed (172, 46%) or suspected (202, 54%) COVID-19 349 
were reported by clinicians from 25 countries (including UK [135, 36%], Italy [80, 21%], 350 
Spain [56, 15%]; Table E3). Demographic and clinical characteristics are summarized in Table 351 
I. The median age was 50 years (IQR 41-58). There was a predominance of males (227, 61%) 352 
and individuals of white ethnicity (316, 85%). Among 304 patients with known smoking 353 
status, 165 (54%) had never smoked and 44 (15%) were current smokers. The majority of 354 
patients had plaque psoriasis (365, 98%) and clear/nearly clear/mild psoriasis at COVID-19 355 
onset (298, 80%). The most commonly reported comorbidities were obesity (123, 33%), 356 
hypertension (97, 26%), psoriatic arthritis (96, 26%) and diabetes (61, 16%).  357 
Most patients were receiving a biologic treatment (267, 71%) for their psoriasis rather than 358 
a non-biologic systemic agent (67, 18%) or no systemic therapy (36, 10%). Of those receiving 359 
a biologic, similar numbers of patients were receiving either a TNF, IL-17 or IL-23 inhibitor 360 
(99, 78 and 90, respectively). Demographic and clinical characteristics by biologic class are 361 
summarized in Table E4, and split by confirmed and suspected COVID-19 in Table E5.  362 
 363 
Most reported patients fully recovered from COVID-19  364 
Three hundred and forty-eight (93%) of the reported patients fully recovered from COVID-365 
19 (Table II). The most common COVID-19 symptoms were fever (244, 68%), fatigue (174, 366 
48%) and dry continuous cough (167, 46%), and the median duration of symptoms was 14 367 
days (IQR 7-21).  368 
Seventy-seven patients (21%) were hospitalized for COVID-19, seven (2%) required high flow 369 
oxygen supplementation and 12 (3%) mechanical ventilation. The median length of hospital 370 
stay was 11 days (IQR 6-20). Nine patients died (2%); their median age was 65 years (range 371 
43 to 89 years), and all had at least one comorbidity, with hypertension (6, 67%) and 372 
diabetes (5, 56%) being the most prevalent. COVID-19 outcomes by biologic class are 373 
summarized in Table E6, and split by confirmed and suspected COVID-19 in Table E7.     374 
 375 
Rates of hospitalization differed by psoriasis treatment type, in addition to established 376 
risk factors for COVID-19 377 
After excluding nine individuals due to unknown drug type (clinical trial participants), 378 
unknown hospitalization status or unknown COVID-19 outcome, 365 patients with psoriasis 379 
were available to assess factors associated with hospitalization. Rates of hospitalization for 380 
COVID-19 were higher among males (26%, versus 12% among females), older patients (60% 381 
among over-70s, versus 26% among 50-70 year-olds and 10% below age 50) and non-white 382 
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ethnicity (32%, versus 19% among white ethnicity). Comorbidities were also highly 383 
prevalent: 76% of hospitalized patients were reported to have hypertension, cardiovascular 384 
disease, diabetes, chronic liver disease or chronic lung disease (including asthma), compared 385 
to 34% of non-hospitalized patients. 386 
Hospitalization for COVID-19 was less common among patients receiving biologic therapy 387 
for their psoriasis (at or up to four weeks prior to COVID-19 onset; 44 of 265, 17%) than 388 
among those receiving non-biologic systemic therapy (22 of 65, 34%) or no systemic therapy 389 
(10 of 35, 29%). Patients receiving biologic therapy also had lower rates of mechanical 390 
ventilation (3%, versus 5% among those receiving non-biologics) and death (2%, versus 5%).  391 
Compared to the reference group of biologic users, an age- and sex-adjusted model for 392 
hospitalization rate estimated an odds ratio of 2.72 for non-biologic systemic users and a 393 
95% CI that did not cross unity (1.37-5.40) (Table III).  394 
To account for potential confounding from a range of established COVID-19 risk factors, a 395 
fully adjusted multivariable logistic regression model was fitted (Table III). Significant 396 
associations with increased hospitalization rate were observed for age (OR 1.59 per 10 397 
years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 398 
95% CI 1.24-8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Despite 399 
imprecise 95% CIs, elevated risk of hospitalization was suggested for several comorbidities 400 
with odds ratios above 2: hypertension (2.03, 95% CI 0.99-4.16), cardiovascular disease 401 
(2.01, 95% CI 0.74-5.46) and chronic liver disease (2.12, 95% CI 0.81, 5.55). No association 402 
was found with having ever smoked (OR 1.16, 95% CI 0.54-2.49).  403 
In the fully adjusted model, non-biologic systemic therapy for psoriasis remained associated 404 
with increased risk of hospitalization compared with the group of biologic users (OR 2.84, 405 
95% CI 1.31-6.18). Patients receiving no systemic therapy were estimated to have a similarly 406 
increased risk of hospitalization (OR 2.35, 95% CI 0.82-6.72). This suggests that use of 407 
biologics is associated with a reduced risk of hospitalization compared with either non-408 
biologic systemic therapy or no therapy, although interpretation of these estimates should 409 
take into account possible sources of bias (as detailed in the discussion).  410 
Patients reported in Spain were more likely to have been hospitalized for COVID-19 (43%, 411 
versus 17% elsewhere) and more likely to receive a non-biologic systemic agent (30%, 412 
versus 16% elsewhere), which could potentially confound the estimated association 413 
between treatment type and hospitalization. Although country of assessment was included 414 
in the fully adjusted model (Spain OR 4.79, 95% CI 1.88-12.19), a sensitivity test using only 415 
non-Spanish patients identified broadly similar effect size estimates for treatment type 416 
(Table E8). A multiple regression model fitted in confirmed cases only (Table E9) indicated a 417 
stronger association with hospitalization risk for use of non-biologic systemic agents 418 
compared with biologics (OR 3.98, 95% CI 1.38-11.46). However, this estimate is likely 419 
inflated since most hospitalized patients had confirmed COVID-19 (69 of 76, 91%). 420 
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To assess potential differences in COVID-19 hospitalization risk between classes of biologics, 421 
a multiple logistic regression model was fitted in which biologics were split into TNF, IL-23 422 
and IL-17 inhibitor groups (n = 98, 89 and 78, respectively) (Table E10). Hospitalization was 423 
observed more frequently in patients receiving IL-23 inhibitors (23%) than those on TNF 424 
(14%) or IL-17 inhibitors (13%); a fully adjusted odds ratio of 1.65 for the IL-23 inhibitor 425 
group was estimated relative to the TNF inhibitor group. However, the 95% confidence 426 
interval was wide (0.64-4.25) and the split by biologic type did not significantly improve 427 
model fit (P = 0.48).  428 
The limited numbers of patients using combination therapy or any individual agent 429 
precluded analysing their association with hospitalization. 430 
 431 
Risk-mitigating behaviours may vary between psoriasis patients receiving biologics and 432 
those receiving non-biologic systemic therapies 433 
To help inform our interpretation of hospitalization rates among psoriasis patients receiving 434 
different types of therapy, we investigated potential differences in COVID-19 risk mitigating 435 
behaviours. Self-reported data from 1,626 individuals with psoriasis (with and without 436 
COVID-19) from 48 countries were available (Table E3). Baseline characteristics including 437 
demographics, psoriasis phenotype and comorbidities are summarized in Table IV. These 438 
were similar to the clinician-reported registry, except for sex (female predominance in the 439 
self-report registry, 64%). Of 96 patients (6%) who self-reported suspected or confirmed 440 
COVID-19, 25 (26%) were receiving a biologic, 13 (14%) a non-biologic systemic agent and 58 441 
(60%) no treatment.  442 
To assess baseline risk-mitigating behaviours, we interrogated self-reported data from 443 
individuals without COVID-19 infection (n=1,476). Four hundred and seventy-eight (32%) 444 
individuals reported receiving a biologic and 249 (17%) a non-biologic systemic agent for 445 
psoriasis during the pandemic. Individuals in both treatment groups had similar baseline 446 
characteristics such as age, ethnicity and comorbidity rates (including obesity, hypertension, 447 
cardiovascular disease, psoriatic arthritis). Reported rates of social isolation (shielding: 448 
quarantine, distancing within the home; or self-isolation: staying home, avoiding others) 449 
were higher in those receiving biologics for psoriasis (346 of 478, 72%) compared with those 450 
receiving non-biologic systemic therapies (161 of 249, 65%; age- and sex-adjusted OR 0.68, 451 
95% CI 0.50-0.94) and those receiving no systemic therapy (470 of 747, 63%; OR 0.63, 95% 452 
CI 0.50-0.80). However, treatment non-adherence rates were slightly lower with 17% (79) of 453 
those receiving biologics and 20% (48) of those receiving non-biologic systemic therapies 454 
reporting stopping treatment during the pandemic. These independent patient-reported 455 
data suggest there may be potential variation in COVID-19 risk-mitigating behaviour 456 
between treatment groups.  457 
 458 
459 
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Discussion 460 
Summary of main findings 461 
We present the largest and first global case series of COVID-19 in people with psoriasis. Of 462 
374 patients from 25 countries reported by clinicians, 93% fully recovered from COVID-19. 463 
Older age, male sex and non-white ethnicity were associated with greater risk of 464 
hospitalization for COVID-19, in addition to chronic lung disease. Comorbidities such as 465 
hypertension, cardiovascular disease and chronic liver disease were more prevalent in 466 
hospitalized patients compared to those not hospitalized. Our data also indicate an 467 
association between use of biologics for psoriasis and reduced risk of hospitalization, in 468 
comparison to non-biologic systemic therapies. We cannot exclude the possibility that  469 
unmeasured confounders may be driving this association: for example, our patient-reported 470 
data (1,626 participants across 48 countries) suggest that COVID-19 risk-mitigating 471 
behaviours (social isolation) may differ between psoriasis treatment groups. Finally, no 472 
significant difference was found in risk of hospitalization between different classes of 473 
biologics. Further investigation of the higher rate of hospitalization observed among 474 
patients using IL-23 inhibitors (compared with TNF or IL-17 inhibitors) in larger datasets is 475 
warranted. 476 
 477 
Comparison with the literature 478 
The baseline characteristics of our international case series suggest our findings are likely to 479 
be applicable to people with moderate to severe psoriasis since 90% of those reported were 480 
taking systemic therapies and there was a high prevalence of comorbidities (7,35). Our 481 
study underscores older age, male sex, non-white ethnicity and comorbidities as important 482 
risk factors for adverse COVID-19 outcomes in people with psoriasis, which is consistent 483 
with those risk factors already established for the general population (2,6). A cohort study of 484 
17 million adults in the UK found that death from COVID-19 was associated with 485 
comorbidities including cardiovascular disease, diabetes, obesity, reduced kidney function 486 
and chronic liver disease (6). Similarly, a case series of 44,672 COVID-19 patients in China 487 
showed that cardiovascular disease, hypertension and diabetes were risk factors for death 488 
(4). There are very limited data in psoriasis, with four regional psoriasis case series in 489 
Northern Italy suggesting no increased rate of hospitalization or death from COVID-19 in 490 
those receiving biologics compared to the local population (17–20). Only six patients were 491 
hospitalized across the four reports, with few non-severe COVID-19 patients captured (n=5 492 
(17), n=8 (18), not reported (19,20)), hence risk factors for adverse COVID-19 outcome could 493 
not be characterized. We addressed this through a larger collection of cases, which was 494 
more diverse with respect to geography, psoriasis therapies and COVID-19 severity and 495 
outcomes. The comprehensive capture of clinician-reported demographic and clinical 496 
variables enabled adjustment for important covariates in our logistic regression analysis.     497 
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Our finding of differential hospitalization risk associated with different treatment groups 498 
builds on the emerging literature across IMIDs. A recent single-centre COVID-19 case series 499 
from New York of 86 patients with IMIDs (14 of whom had psoriasis) observed that use of 500 
biologics was lower among those hospitalized for COVID-19 (6 of 14, 43%) than those not 501 
hospitalized (50 of 72, 69%) (36). Use of non-biologic systemic agents, including the 502 
common psoriasis therapy methotrexate, was higher among hospitalized patients than 503 
those not hospitalized.  504 
Our data also aligns with findings from global clinician-reporting COVID-19 registries in 505 
inflammatory bowel disease (IBD; 525 patients across 33 countries) and rheumatic disease 506 
(600 patients across 40 countries) (28,29). The hospitalization and case fatality rates were 507 
31% and 3% respectively in IBD, and 46% and 9% respectively in rheumatic disease (versus 508 
21% and 2% in our psoriasis dataset). Severe COVID-19 was associated with older age and 509 
comorbidities in both studies. TNF inhibitor use was associated with decreased risk of 510 
COVID-19-related hospitalization among patients with rheumatic disease (OR 0.4, 95% CI 511 
0.19-0.81) and decreased risk of hospitalization or death in IBD (OR 0.6, 95% CI 0.38-0.96). 512 
These findings, together with our data, contrast with pre-COVID-19 observational data, in 513 
which use of biologics including TNF inhibitors was associated with an increased risk of 514 
serious infections (for example, a higher incidence of lower respiratory tract 515 
infections/pneumonia has been observed for infliximab compared with methotrexate) 516 
(10,11). A meta-estimate of phase III randomized controlled trials of IL-17 inhibitors in 517 
psoriasis also indicated an increased risk of respiratory tract infections compared to placebo 518 
(OR 1.31, 95% CI 1.05-1.62) (37), however a similar analysis (albeit it with smaller sample 519 
sizes) found no statistically significant signal associated with IL-23 inhibitor use (OR 1.15, 520 
95% CI 0.88-1.49) (38). Phase III trial data also suggest that use of psoriasis biologics (TNF, IL-521 
17 and IL-23 inhibitors) is not associated with increases in viral infections such as influenza 522 
compared with placebo (39), which is consistent with data from long-term registries (10) 523 
and studies of other IMIDs (40).  524 
 525 
Given the cytokine upregulation from aberrant immune activation observed in severe 526 
COVID-19, there is biological plausibility for a protective effect of cytokine-targeted biologics 527 
on adverse outcomes, compared with broader immunosuppressants that may detrimentally 528 
suppress host anti-viral immunity (41). This notion is currently under evaluation in trials of 529 
re-purposed IMID biologics in patients with COVID-19 (42). Existing reports of elevated 530 
plasma levels of TNF and IL-17 in patients manifesting severe COVID-19 (31) also align with 531 
our observation of a lower hospitalization rate in individuals receiving TNF inhibitors or IL-17 532 
inhibitors compared to those receiving IL-23 inhibitors. Given the close interplay between IL-533 
17 and IL-23 cytokines (IL-23 promotes the terminal differentiation, proliferation and 534 
activation of IL-17 secreting Th17 cells (43)) and the more established role of the IL-23/IL-17 535 
axis in bacterial and fungal immunity (as opposed to viral defence), these observations 536 
require further study. We were unable to draw firm conclusions since our sample numbers 537 
limited the power to detect all but large differences in hospitalization risk between biologic 538 
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classes. Inhibitors of TNF, IL-17 and IL-23 are widely used for the treatment of moderate-539 
severe psoriasis, so further accrual of cases over time will enable more robust interrogation 540 
of the differential risks associated with different biologic classes, which has important 541 
implications for clinical practice.   542 
Alternatively, the association between use of biologics and reduced hospitalization may not 543 
be causal, but rather due to unmeasured confounders. Our patient-reported data suggest 544 
increased risk-mitigating behaviour (social isolation) in individuals receiving biologics 545 
compared with those receiving non-biologic systemic agents, which may reflect public 546 
perceptions of differential risk associated with different treatments. Social isolation may 547 
influence the initial exposure dose of SARS-CoV-2, which may affect the viral load and 548 
clinical course of COVID-19. Behavioural variation between treatment groups, and the 549 
consequent impact on COVID-19 risk/severity, warrants urgent further investigation since it 550 
is potentially relevant for public health policy.  551 
 552 
Strengths and limitations 553 
Major strengths are the global reach and size of the case series. The speed with which data 554 
has been accrued has enabled the timely release of results in response to the current global 555 
public health emergency. As the largest international study of COVID-19 outcomes in 556 
patients with psoriasis, our findings are more generalisable than the regional reports 557 
published to date. The key demographic associations with hospitalization for COVID-19 (sex, 558 
age, ethnicity) in our psoriasis dataset are in keeping with prior findings in the general 559 
population, which suggests robust data capture. We also present independent global 560 
patient-reported data on risk-mitigating behaviours during the pandemic, thus addressing 561 
for the first time a potential unmeasured confounder in clinician-reported datasets.  562 
Information on the registries was disseminated worldwide, but the larger numbers of 563 
patients from Spain, Italy and UK (albeit areas of high COVID-19 prevalence) indicate 564 
potential ascertainment bias, which limits the generalizability of the results. Although our 565 
hospitalization rate of 22% is comparable to other global IMID registries, more severe 566 
COVID-19 cases may be over-represented since these may have been preferentially brought 567 
to the attention of clinicians. In contrast, patients who have died or those remaining in 568 
hospital may not yet have been reported. The higher hospitalization rate in Spain may 569 
represent a selective capture of severe cases or different international thresholds for 570 
hospital admission; the latter is a limitation of using hospitalization as a proxy for severe 571 
COVID-19. Reassuringly, a sensitivity analysis excluding Spanish cases did not change our 572 
conclusions, and differences in rates of death and mechanical ventilation among psoriasis 573 
patients receiving biologics versus non-biologic systemic therapies were consistent with our 574 
primary findings for hospitalization. Diverse COVID-19 testing practices may also have 575 
affected reporting (e.g. preferential testing of severe/hospitalized patients), although we 576 
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encouraged submission of suspected cases and our sensitivity analysis restricted to patients 577 
with only confirmed COVID-19 yielded similar results to the main analysis.  578 
Our case series is dominated by patients with moderate-severe psoriasis, therefore our 579 
findings may not be generalisable to those with milder psoriasis. The majority of clinician-580 
reported cases were receiving biologics, which contrasts with our patient-reported data. If 581 
this represents a different propensity for clinicians to report patients on different treatment 582 
types, then together with a higher likelihood of hospitalized cases being reported, this could 583 
lead to inflated effect size estimates due to selection bias. In contrast to clinician-reported 584 
data, a potential limitation of the self-report dataset is exposure misclassification, but it is 585 
reassuring that the overall baseline characteristics of both registries are comparable.  586 
Although not an objective of this study, the clinical course of COVID-19 in individuals with 587 
and without psoriasis cannot be compared due to the lack of a matched control group from 588 
the general population. COVID-19 outcomes in those receiving biologics in our study also 589 
cannot be directly compared to studies of the general population due to fundamental 590 
differences in the ascertainment of cases. However, the observed median length of hospital 591 
stay and COVID-19 symptom characteristics in our biologic-treated clinician-reported case 592 
series are similar to those published on general populations. For example, the median 593 
length of hospital stay for psoriasis patients with COVID-19 who were receiving biologics in 594 
our study (14 days [IQR 6-23 days]) is similar to that of 1099 hospitalized patients with 595 
COVID-19 across 552 hospitals in China (12 days [IQR 10-14 days])(44). The most common 596 
three symptoms of COVID-19 in both the Chinese cohort and our patients receiving psoriasis 597 
biologics were fever, cough and fatigue. 598 
The incidence of COVID-19 in psoriasis cannot be determined due to the lack of 599 
denominator (source population) data and uncertainty regarding those psoriasis patients 600 
with COVID-19 who were not reported. The incidence of COVID-19 in individuals receiving 601 
particular therapies also cannot be deduced, however future linkage to pharmacovigilance 602 
registry data should facilitate this.  603 
 604 
Conclusions 605 
In this large international series of patients with psoriasis and COVID-19, use of biologics 606 
was associated with a reduced risk of adverse COVID-19 outcome when compared to non-607 
biologic systemic agents. This effect appeared to be primarily associated with use of TNF 608 
and IL-17 inhibitors, however further investigation of the observed differential rate of 609 
hospitalization between different classes of biologics is warranted. The accumulation of 610 
further data is required to clarify these observations before any recommendations for 611 
changes in clinical practice can be considered. Possible selection bias should be addressed 612 
through robust global clinician and patient participation in COVID-19 registries and 613 
alternative study designs such as cohort studies. This will open avenues for characterising 614 
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the determinants of additional COVID-19 outcomes and the impacts of specific treatments 615 
at higher resolution. 616 
 617 
 618 
 619 
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Table I – Demographic and clinical characteristics of clinician-reported patients with 
psoriasis and COVID-19 
 
 
 All patients 
 
Biologics 
 
Non-biologic 
systemic 
therapy 
No systemic 
agent 
 
Missing 
 
 n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n 
N 374 267 67 36   
Sex         0 
  Female 147 (39.3) 107 (40.1) 29 (43.3) 9 (25.0)   
  Male 227 (60.7) 160 (59.9) 38 (56.7) 27 (75.0)   
Age (years) 50 (41-58) 50 (42-57) 49 (40-60) 53 (35-63) 0 
Ethnicity         3 
  White 316 (85.2) 230 (86.5) 57 (86.4) 27 (77.1)   
  South Asian 21 (5.7) 16 (6.0) 3 (4.5) 2 (5.7)   
  Hispanic or Latino 19 (5.1) 13 (4.9) 3 (4.5) 1 (2.9)   
  Other 15 (4.0) 7 (2.6) 3 (4.5) 5 (14.3)   
Country of assessment         0 
  United Kingdom 135 (36.1) 103 (38.6) 21 (31.3) 11 (30.6)   
  Italy 80 (21.4) 69 (25.8) 11 (16.4) 0 (0.0)   
  Spain 56 (15.0) 35 (13.1) 16 (23.9) 3 (8.3)   
  United States 25 (6.7) 15 (5.6) 2 (3.0) 8 (22.2)   
  France 24 (6.4) 14 (5.2) 6 (9.0) 4 (11.1)   
  Netherlands 11 (2.9) 7 (2.6) 4 (6.0) 0 (0.0)   
  Rest of Europe 22 (5.9) 16 (6.0) 3 (4.5) 3 (8.3)   
  Rest of the world 21 (5.6) 8 (3.0) 4 (6.0) 7 (19.4)   
Psoriasis phenotype         1 
  Plaque 365 (97.9) 263 (98.5) 63 (94.0) 35 (100.0)   
  Pustular 8 (2.1) 4 (1.5) 4 (6.0) 0 (0.0)   
Psoriatic arthritis         0 
  No 238 (63.6) 162 (60.7) 48 (71.6) 26 (72.2)   
  Yes 96 (25.7) 78 (29.2) 15 (22.4) 1 (2.8)   
  Unknown 40 (10.7) 27 (10.1) 4 (6.0) 9 (25.0)   
Baseline psoriasis severity 
(PGA)         1 
  Clear 87 (23.3) 72 (27.0) 9 (13.4) 5 (14.3)   
  Nearly clear 113 (30.3) 99 (37.1) 6 (9.0) 7 (20.0)   
  Mild 98 (26.3) 59 (22.1) 27 (40.3) 11 (31.4)   
  Moderate 51 (13.7) 22 (8.2) 21 (31.3) 7 (20.0)   
  Moderate-severe 18 (4.8) 11 (4.1) 4 (6.0) 3 (8.6)   
  Severe 6 (1.6) 4 (1.5) 0 (0.0) 2 (5.7)   
Months on treatment 24.0 (9.2-49.7) 23.2 (9.3-48.2) 25.8 (9.2-65.6) - 21 
Treatment stopped during COVID-19        0 
  Yes 185 (55.4) 143 (53.6) 42 (62.7) -   
  No 139 (41.6) 117 (43.8) 22 (32.8) -   
  Unknown 10 (3.0) 7 (2.6) 3 (4.5) -   
Biologic type         0 
  TNF inhibitor 99 (37.1) 99 (37.1) - -   
  IL-23 inhibitor 90 (33.7) 90 (33.7) - -   
  IL-17 inhibitor 78 (29.2) 78 (29.2) - -   
Measures of obesity           
BMI 27.4 (24.8-33.1) 28.4 (25.1-34.2) 27.5 (23.8-32.0) 25.6 (23.9-26.9) 73 
Obesity 123 (32.9) 96 (36.0) 22 (32.8) 5 (13.9) 0 
Comorbidities           
Hypertension 97 (25.9) 71 (26.6) 18 (26.9) 7 (19.4) 0 
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Diabetes 61 (16.3) 44 (16.5) 11 (16.4) 6 (16.7) 0 
Anxiety or depression 40 (10.7) 27 (10.1) 9 (13.4) 3 (8.3) 0 
Cardiovascular disease 36 (9.6) 21 (7.9) 9 (13.4) 6 (16.7) 0 
Chronic liver disease 31 (8.3) 24 (9.0) 3 (4.5) 3 (8.3) 0 
Asthma 25 (6.7) 18 (6.7) 6 (9.0) 1 (2.8) 0 
Cancer (incl. remission) 15 (4.0) 8 (3.0) 4 (6.0) 3 (8.3) 0 
COPD or other chronic lung 
disease 14 (3.7) 11 (4.1) 1 (1.5) 2 (5.6) 0 
Chronic kidney disease 9 (2.4) 5 (1.9) 3 (4.5) 1 (2.8) 0 
Alcohol excess 8 (2.1) 4 (1.5) 3 (4.5) 1 (2.8) 0 
ACEi at onset 41 (12.8) 31 (13.4) 6 (10.0) 3 (12.5) 54 
ARB at onset 41 (12.7) 27 (11.5) 11 (18.0) 2 (8.3) 50 
NSAID at onset 26 (8.3) 19 (8.4) 3 (5.1) 2 (8.3) 60 
Smoking 70 
  Current smoker 44 (14.5) 34 (15.5) 7 (13.5) 3 (10.0)   
  Former smoker 95 (31.2) 66 (30.1) 19 (36.5) 9 (30.0)   
  Never smoked 165 (54.3) 119 (54.3) 26 (50.0) 18 (60.0)   
Table footnotes 
4 participants excluded from treatment groups due to unknown drug (clinical trial) 
‘Biologics’ category includes participants reporting co-therapy with conventional systemic or steroids (15), small molecule inhibitor 
(0) or both (0) 
'Non-biologic systemic therapy' category includes participants reporting conventional systemic or steroids (39), small molecule 
inhibitor (26) or both (2) 
Plaque psoriasis phenotype includes 1 patient with erythroderma and 3 with plaque and erythroderma. Pustular psoriasis 
phenotype includes 3 with plaque and/or erythroderma also present. 
13 records imported directly from the AAD COVID-19 registry were assumed to have plaque psoriasis. 
For patients on multiple systemic therapies, time on treatment was measured from the latest date (i.e. start of co-therapy) 
For patients on multiple systemic therapies, treatment stoppage was taken as stopping any of the treatments. 
'Obesity' combines patients for whom obesity is selected as a comorbidity with those having BMI >30. It may therefore miss some 
of the 73 patients for whom BMI is not available. 
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Table II – COVID-19 outcomes in clinician-reported psoriasis patients 
 
 
 
All patients 
 
Biologics 
 
Non-biologic 
systemic therapy 
No systemic 
agent 
Missing 
 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n 
N 374 267 67 36   
COVID-19 diagnosis 0 
  Suspected 202 (54.0) 154 (57.7) 33 (49.3) 15 (41.7)   
  Confirmed 172 (46.0) 113 (42.3) 34 (50.7) 21 (58.3)   
COVID-19 outcome 0 
  Unresolved 4 (1.1) 2 (0.7) 2 (3.0) 0 (0.0)   
  Recovery 348 (93.0) 254 (95.1) 60 (89.6) 30 (83.3)   
  Chronic complication 13 (3.5) 7 (2.6) 2 (3.0) 4 (11.1)   
  Death 9 (2.4) 4 (1.5) 3 (4.5) 2 (5.6)   
Hospitalization 4 
  Hospitalized 77 (20.8) 44 (16.6) 22 (33.8) 10 (27.8)   
  Not hospitalized 292 (78.9) 221 (83.4) 43 (66.2) 25 (69.4)   
  Unknown 1 (0.3) 0 (0.0) 0 (0.0) 1 (2.8)   
Level of hospital care (% among all cases)   
No supplementary oxygen 8 (2.2) 4 (1.5) 1 (1.5) 3 (8.6) 5 
Oxygen via mask 42 (11.4) 20 (7.5) 16 (24.6) 6 (17.1) 5 
Non-invasive vent./hi flow 7 (1.9) 5 (1.9) 2 (3.1) 0 (0.0) 5 
Mechanical ventilation 12 (3.3) 9 (3.4) 3 (4.6) 0 (0.0) 5 
Ventilation (unknown type) 3 (0.8) 3 (1.1) 0 (0.0) 0 (0.0) 5 
Unknown interventions 8 (2.2) 5 (1.9) 1 (1.5) 1 (2.9) 5 
Composite outcome: 
mechanical ventilation or 
death 
20 (5.4) 12 (4.5) 6 (9.2) 2 (5.6) 4 
Days in hospital 11 (6-20) 14 (6-23) 10 (5-19) 10 (8-18) 13 
Asymptomatic 12 (3.2) 9 (3.4) 1 (1.5) 2 (5.6) 4 
Common COVID-19 symptoms (% among symptomatic cases)   
Fever 244 (69.7) 168 (67.5) 51 (81.0) 22 (64.7) 12 
Fatigue (Malaise) 174 (49.7) 123 (49.4) 35 (55.6) 15 (44.1) 12 
Dry continuous cough 167 (47.7) 119 (47.8) 31 (49.2) 15 (44.1) 12 
Muscle aches (Myalgia) 130 (37.1) 92 (36.9) 21 (33.3) 15 (44.1) 12 
Shortness of breath 
(Dyspnea) 
116 (33.1) 87 (34.9) 18 (28.6) 10 (29.4) 12 
Anosmia and/or dysgeusia 83 (23.7) 62 (24.9) 13 (20.6) 8 (23.5) 12 
Joint pain (Arthralgia) 64 (18.3) 49 (19.7) 11 (17.5) 2 (5.9) 12 
Sore throat 62 (17.7) 45 (18.1) 14 (22.2) 3 (8.8) 12 
Headache 49 (14.0) 39 (15.7) 7 (11.1) 3 (8.8) 12 
Diarrhoea 42 (12.0) 23 (9.2) 16 (25.4) 3 (8.8) 12 
Chest pain 31 (8.9) 25 (10.0) 4 (6.3) 1 (2.9) 12 
Cough with sputum 
production 
26 (7.4) 20 (8.0) 5 (7.9) 0 (0.0) 12 
Runny nose (Rhinorrhea) 26 (7.4) 20 (8.0) 1 (1.6) 5 (14.7) 12 
Wheezing 25 (7.1) 20 (8.0) 3 (4.8) 2 (5.9) 12 
Nausea and/or vomiting 20 (5.7) 9 (3.6) 6 (9.5) 5 (14.7) 12 
Abdominal pain 13 (3.7) 9 (3.6) 1 (1.6) 3 (8.8) 12 
Conjunctivitis 10 (2.9) 8 (3.2) 1 (1.6) 1 (2.9) 12 
Days of COVID-19 
symptoms 
14 (7-21) 14 (7-21) 14 (10-22) 10 (7-18) 18 
Table footnotes 
4 participants excluded from treatment groups due to unknown drug (clinical trial) 
‘Biologics’ category includes participants reporting co-therapy with conventional systemic or steroids (15), small molecule inhibitor 
(0) or both (0) 
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'Non-biologic systemic therapy' category includes participants reporting conventional systemic or steroids (39), small molecule 
inhibitor (26) or both (2) 
4 patients with unresolved COVID-19 are excluded from COVID-19 outcome summaries (treated as missing) 
Symptom of ‘unspecified cough’ allocated to 'dry continuous cough' (2 patients) 
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Table III –Multivariate logistic regression models for hospitalization due to COVID-19 
 
 
  
Counts 
n hospitalized/ 
total n (%) 
Minimally adjusted 
model 
OR (95% CI) 
Fully adjusted 
model 
OR (95% CI) 
Treatment type   
  Biologic 44/265 (16.6) Ref Ref 
  Non-biologic systemic 22/65 (33.8) 2.72 (1.37, 5.40) 2.84 (1.31, 6.18) 
  No systemic agent 10/35 (28.6) 1.88 (0.75, 4.68) 2.35 (0.82, 6.72) 
Male 58/220 (26.4) 2.29 (1.22, 4.32) 2.51 (1.23, 5.12) 
Age (effect per 10 years) - 2.01 (1.59, 2.52) 1.59 (1.19, 2.13) 
Non-white ethnicity 17/53 (32.1) - 3.15 (1.24, 8.03) 
Assessment country   
  United Kingdom 19/133 (14.3) - Ref 
  Spain 23/53 (43.4) - 4.79 (1.88, 12.19) 
  Rest of Europe 23/136 (16.9) - 1.61 (0.70, 3.72) 
  Rest of the world 11/43 (25.6) - 1.27 (0.43, 3.79) 
BMI (effect per 5 kg/m2) - - 1.09 (0.87, 1.37) 
Hypertension 38/93 (40.9) - 2.03 (0.99, 4.16) 
Cardiovascular disease 20/34 (58.8) - 2.01 (0.74, 5.46) 
Chronic liver disease 14/30 (46.7) - 2.12 (0.81, 5.55) 
Diabetes 22/60 (36.7) - 1.05 (0.46, 2.38) 
Chronic lung disease (incl. 
asthma, COPD) 
16/38 (42.1) - 3.87 (1.52, 9.83) 
Other comorbidities 30/77 (39.0) - 1.69 (0.83, 3.43) 
Ever smoked 34/136 (25.0) - 1.16 (0.54, 2.49) 
 
Table footnotes 
‘Ref’ is the reference group in the multivariable logistic regression models.  Jo
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Table IV – Characteristics self-reported to the PsoProtectMe registry by individuals with 
psoriasis during the COVID-19 pandemic 
 
 
 
 
All patients 
 
Biologics 
 
Non-biologic 
systemic 
therapy 
No systemic 
agent 
 
Missing 
 
 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n (%) or 
median (IQR) 
n 
N 1,626 512 273 839   
COVID infection 0 
  Yes, with test 15 (0.9) 1 (0.2) 2 (0.7) 12 (1.4)   
  Yes, no test 81 (5.0) 24 (4.7) 11 (4.0) 46 (5.5)   
  Unsure 54 (3.3) 9 (1.8) 11 (4.0) 34 (4.1)   
  No 1,476 (90.8) 478 (93.4) 249 (91.2) 747 (89.0)   
Age (years) 48 (36-59) 49 (39-58) 50 (38-60) 46 (33-60) 0 
Sex 0 
  Female 1,041 (64.0) 287 (56.1) 184 (67.4) 570 (67.9)   
  Male 583 (35.9) 223 (43.6) 89 (32.6) 269 (32.1)   
  Unknown 2 (0.1) 2 (0.4) 0 (0.0) 0 (0.0)   
Ethnicity 19 
  White 1,399 (87.1) 436 (85.8) 231 (85.2) 730 (88.4)   
  Non-white 208 (12.9) 72 (14.2) 40 (14.8) 96 (11.6)   
Country of assessment 2 
  United Kingdom 1,191 (73.3) 370 (72.3) 206 (75.5) 614 (73.4)   
  United States 98 (6.0) 48 (9.4) 11 (4.0) 39 (4.7)   
  Denmark 49 (3.0) 25 (4.9) 4 (1.5) 20 (2.4)   
  Sweden 33 (2.0) 10 (2.0) 7 (2.6) 16 (1.9)   
  Philippines 31 (1.9) 1 (0.2) 6 (2.2) 24 (2.9)   
  Canada 27 (1.7) 10 (2.0) 6 (2.2) 10 (1.2)   
  Ireland 26 (1.6) 8 (1.6) 1 (0.4) 17 (2.0)   
  Hong Kong 16 (1.0) 5 (1.0) 2 (0.7) 9 (1.1)   
  Norway 14 (0.9) 6 (1.2) 4 (1.5) 4 (0.5)   
  Australia 14 (0.9) 7 (1.4) 0 (0.0) 7 (0.8)   
  Singapore 11 (0.7) 0 (0.0) 4 (1.5) 7 (0.8)   
  Japan 10 (0.6) 7 (1.4) 2 (0.7) 1 (0.1)   
  Rest of Europe 53 (3.3) 9 (1.8) 4 (1.5) 40 (4.8)   
  Rest of the world 51 (3.1) 6 (1.2) 16 (5.9) 29 (3.5)   
Psoriasis phenotype 20 
  Plaque 1,446 (90.0) 457 (91.0) 232 (85.9) 755 (90.7)   
  Pustular 104 (6.5) 35 (7.0) 28 (10.4) 41 (4.9)   
  Unsure 56 (3.5) 10 (2.0) 10 (3.7) 36 (4.3)   
Psoriatic arthritis 0 
  Yes 548 (33.7) 246 (48.0) 128 (46.9) 173 (20.6)   
  No 993 (61.1) 243 (47.5) 128 (46.9) 621 (74.0)   
  Unsure 85 (5.2) 23 (4.5) 17 (6.2) 45 (5.4)   
Baseline psoriasis severity (self-reported using PGA scale) 0 
  Clear 218 (13.4) 158 (30.9) 23 (8.4) 36 (4.3)   
  Nearly clear 364 (22.4) 184 (35.9) 60 (22.0) 119 (14.2)   
  Mild 423 (26.0) 88 (17.2) 68 (24.9) 267 (31.8)   
  Moderate 359 (22.1) 40 (7.8) 73 (26.7) 246 (29.3)   
  Moderate-severe 188 (11.6) 30 (5.9) 32 (11.7) 126 (15.0)   
  Severe 63 (3.9) 9 (1.8) 16 (5.9) 38 (4.5)   
  Not sure 11 (0.7) 3 (0.6) 1 (0.4) 7 (0.8)   
Months on treatment (COVID-19 group, 
at onset) 
25.3 (6.0-51.0) 23.4 (9.2-49.8) 27.7 (2.9-51.9) - 11 
Months on treatment (uninfected 25.2 (9.1-60.2) 24.8 (9.5-52.5) 26.1 (7.9-74.4) - 48 
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group, at survey date) 
Treatment stopped during COVID-19 22 (40.7) 11 (35.5) 11 (47.8) - 4 
Treatment stopped during pandemic 
(uninfected group) 
127 (17.9) 79 (17.0) 48 (19.8) - 21 
Biologic type 0 
  TNF inhibitor 225 (43.9) 225 (43.9) - -   
  IL-23 inhibitor 171 (33.4) 171 (33.4) - -   
  IL-17 inhibitor 115 (22.5) 115 (22.5) - -   
  IL-1R inhibitor 1 (0.2) 1 (0.2) - -   
Measures of obesity   
BMI 
26.8 (23.4-
31.2) 
27.9 (24.3-
32.5) 
26.6 (23.3-
31.2) 
26.0 (22.8-
29.8) 114 
Obesity 478 (29.4) 176 (34.4) 91 (33.3) 210 (25.0) 0 
Comorbidities   
Hypertension 344 (21.2) 135 (26.4) 69 (25.3) 139 (16.6) 0 
Diabetes 105 (6.5) 43 (8.4) 14 (5.1) 48 (5.7) 0 
Anxiety or depression 384 (23.6) 120 (23.4) 58 (21.2) 206 (24.6) 0 
Cardiovascular disease 95 (5.8) 26 (5.1) 17 (6.2) 52 (6.2) 0 
Chronic liver disease 81 (5.0) 42 (8.2) 10 (3.7) 29 (3.5) 0 
Asthma 181 (11.1) 66 (12.9) 25 (9.2) 90 (10.7) 0 
Cancer (incl. remission) 43 (2.6) 10 (2.0) 6 (2.2) 27 (3.2) 0 
COPD or other chronic lung disease 44 (2.7) 17 (3.3) 8 (2.9) 19 (2.3) 0 
Chronic kidney disease 16 (1.0) 8 (1.6) 3 (1.1) 5 (0.6) 0 
ACEi user 204 (13.9) 76 (16.8) 41 (16.9) 87 (11.3) 162 
ARB user 140 (10.0) 62 (14.4) 22 (9.7) 55 (7.4) 219 
NSAID user 288 (20.2) 112 (25.2) 39 (17.3) 137 (18.2) 202 
Smoking 28 
  Never smoked 837 (52.4) 254 (50.3) 150 (55.8) 433 (52.7)   
  Former smoker 571 (35.7) 184 (36.4) 88 (32.7) 299 (36.4)   
  Current smoker 190 (11.9) 67 (13.3) 31 (11.5) 90 (10.9)   
Risk-mitigating behaviours (uninfected group)   
Shielding 319 (21.6) 134 (28.0) 54 (21.7) 131 (17.5) 0 
Self-isolating 831 (56.3) 273 (57.1) 130 (52.2) 426 (57.0) 0 
  Shielding or self-isolating 979 (66.3) 346 (72.4) 161 (64.7) 470 (62.9) 0 
Social distancing 989 (67.0) 275 (57.5) 161 (64.7) 552 (73.9) 0 
Wearing gloves or masks 555 (37.6) 190 (39.7) 87 (34.9) 278 (37.2) 0 
Other risk-mitigating behaviour 42 (2.8) 14 (2.9) 3 (1.2) 25 (3.3) 0 
No risk-mitigating behaviour 11 (0.7) 2 (0.4) 2 (0.8) 7 (0.9) 0 
Table footnotes 
2 participants excluded from treatment groups due to unknown drug (clinical trial) 
‘Biologics’ category includes participants reporting co-therapy with conventional systemic or steroids (61), small molecule inhibitor 
(2) or both (3) 
'Non-biologic systemic therapy' category includes participants reporting conventional systemic or steroids (229), small molecule 
inhibitor (39) or both (6) 
Time on treatment and adherence data were excluded for participants reporting multiple biologics (5), multiple conventional 
systemics or steroids (10) or multiple small molecule inhibitors (0) 
For participants reporting systemic treatments in more than one category, time on treatment was measured from the latest date 
(i.e. start of co-therapy) 
Obesity combines participants selecting obesity as a comorbidity with those having BMI >30. It may therefore miss some of the 114 
participants for whom BMI is not available. 
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